Cubist Systematic Strategies, LLC Tg Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

A detailed history of Cubist Systematic Strategies, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 15,200 shares of TGTX stock, worth $442,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,200

Previous 679,020 97.76%

Holding current value

$442,928

Previous $12.1 Million 97.06%

% of portfolio

0.0%

Previous 0.08%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $53,186 - $76,625	-3,993 Reduced 0.58%	679,020 $12.1 Million
Q1 2024 May 15, 2024	BUY	$13.02 - $21.3 $7.95 Million - $13 Million	610,280 Added 839.07%	683,013 $10.4 Million
Q4 2023 Feb 14, 2024	SELL	$6.68 - $18.81 $3.04 Million - $8.55 Million	-454,755 Reduced 86.21%	72,733 $1.24 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $3.98 Million - $12.6 Million	475,738 Added 919.3%	527,488 $4.41 Million
Q2 2023 Aug 14, 2023	SELL	$15.48 - $35.0 $1.34 Million - $3.03 Million	-86,464 Reduced 62.56%	51,750 $1.29 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $1.06 Million - $2.01 Million	103,773 Added 301.31%	138,214 $2.08 Million
Q4 2022 Feb 14, 2023	SELL	$5.01 - $11.83 $683,123 - $1.61 Million	-136,352 Reduced 79.83%	34,441 $407,000
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $653,514 - $1.2 Million	143,001 Added 514.54%	170,793 $1.01 Million
Q2 2022 Aug 15, 2022	SELL	$3.74 - $10.66 $435,687 - $1.24 Million	-116,494 Reduced 80.74%	27,792 $118,000
Q1 2022 May 16, 2022	BUY	$7.81 - $20.45 $953,827 - $2.5 Million	122,129 Added 551.2%	144,286 $1.37 Million
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $336,786 - $786,795	22,157 New	22,157 $421,000
Q3 2021 Nov 15, 2021	SELL	$21.78 - $40.45 $239,580 - $444,950	-11,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $141,992 - $213,906	4,369 Added 65.89%	11,000 $427,000
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $699,048 - $912,240	-16,800 Reduced 71.7%	6,631 $320,000
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $592,101 - $1.29 Million	23,431 New	23,431 $1.22 Million
Q2 2020 Aug 14, 2020	SELL	$8.9 - $21.84 $161,027 - $395,151	-18,093 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$7.14 - $15.99 $1.64 Million - $3.67 Million	-229,271 Reduced 92.69%	18,093 $178,000
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $1.22 Million - $2.67 Million	238,722 Added 2762.35%	247,364 $2.75 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $39,499 - $66,004	7,342 Added 564.77%	8,642 $49,000
Q2 2019 Aug 14, 2019	BUY	$6.27 - $8.65 $8,150 - $11,245	1,300 New	1,300 $11,000
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $91,497 - $153,204	-26,598 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $136,979 - $372,372	26,598 New	26,598 $149,000
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $154,700 - $185,640	-12,376 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $107,671 - $207,916	12,376 New	12,376 $176,000

Others Institutions Holding TGTX

# of Institutions

336

Shares Held

87.6M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account

Cubist Systematic Strategies, LLC Tg Therapeutics, Inc. Transaction History